Epimorphic regeneration and related hydrogel delivery systems

Patent metadata

Field	Value
Publication number	US-11033541-B2
Application number	US-201916429822-A
Country	US
Kind code	B2
Filing date	Jun 3, 2019
Priority date	Nov 13, 2013
Publication date	Jun 15, 2021
Grant date	Jun 15, 2021

Abstract

Methods and compositions are described for enhancing tissue regeneration or wound repair in a mammalian subject comprising a composition comprising (a) a proline hydroxylase inhibitor component or molecule that increases or upregulates HIF1a and (b) a carrier component comprising a hydrogel.

First claim

We claim:

1. A method for enhancing tissue regeneration in a mammalian subject, said method comprising administering to a mammalian subject in need thereof a composition comprising a proline hydroxylase inhibitor component and a hydrogel comprising a chemical ligation product of a first macromonomer component of formula

and a second macromonomer component of formula

wherein each of R1 and R2 is independently selected from hexaglycolic and tripentaerythritolic moieties, each of n1 and n2 is an integer independently selected from 1 to about 201, and Cys is an N-terminal cysteine residue; and a pharmaceutically-acceptable carrier.

2. The method of claim 1 wherein said composition comprises an aqueous medium.

3. The method of claim 1 wherein said composition comprises a hydrogel.

4. The method of claim 1 wherein said proline hydroxylase inhibitor component is selected from 1,4-DPCA, DMOG, DFX, Imiquimod and CoCl 2 .

5. The method of claim 1 comprising systemic administration of said composition.

6. The method of claim 5 wherein said administration is at a site distal from the site of a tissue wound or injury.

7. A method of using a hydrogel system to modulate cellular levels of HIF1a protein, said method comprising:
providing a first hydrogel precursor component comprising an aqueous medium comprising

a second hydrogel precursor component comprising an aqueous medium comprising

wherein each of R1 and R2 is independently selected from hexaglycolic and tripentaerythritolic moieties, each of n1 and n2 is an integer independently selected from 1 to about 201 and Cys is an N-terminal cysteine residue, and a proline hydroxylase inhibitor precursor component comprising 1,4-DPCA coupled to a poly(alkylene oxide) block copolymer;
mixing said precursor components to provide a hydrogel comprising a said coupled 1,4-DPCA component therein; and
administering such a hydrogel to a non-regenerative mammal presenting a tissue injury.

8. The method of claim 7 wherein said administration can be selected from oral intake and subcutaneous, intramuscular, intravenous and intraperitoneal injection.

9. The method of claim 8 wherein said administration can comprise multiple doses over time to provide a constitutive cellular level of HIF1a protein.

Assignees

• Univ Northwestern
• Wistar Inst

Inventors

• Messersmith Phillip B
• Strehin Iossif A
• Heber-Katz Ellen

Classifications

• C08G65/33396 Primary

  having oxygen in addition to nitrogen · CPC title

• C08G2650/58

  Ethylene oxide or propylene oxide copolymers, e.g. pluronics · CPC title

• C08G65/333

  containing nitrogen · CPC title

• C08L2203/02

  for biomedical use · CPC title

• C12Y114/11002

  Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase · CPC title